The False Claims lawsuits alleged that Biogen submitted false claims to Medicare and Medicaid by paying kickbacks to its top physician prescribers to dissuade them from prescribing drugs from competitors.
The lawsuit was filed in Massachusetts in 2012 by whistleblower and former employee Michael Bawduniak. According to the complaint, from Jan. 1, 2009, to March 18, 2014, the company paid remuneration — including in the form of speaker honoraria, speaker training fees, consulting fees and meals — to physicians who attended their speaker programs or consultant programs to induce them to prescribe Avonex, Tysabri and Tecfidera.
Biogen will pay $843.8 million to the U.S. and $56.2 million to 15 states. Mr. Bawduniak will receive approximately 29.6 percent of the settlement’s federal proceeds.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
